Physician profile

Alexander Mut

Surgical · Warwick, RI

NPI 1083268676

$465.51

in general payments reported to CMS, 2019-2025

3 companies · $16.10 in 2025

The $16.10 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$158.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $406.60 2022-2024 Mako, Insignia
Medical Device Business Services, INC. $42.81 2021
Pacira Pharmaceuticals Incorporated $16.10 2025 Iovera

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alexander Mut

$465.51

in general payments reported 2019-2025

Years
2021-2025
Top company
Stryker Corporation
Context
The $16.10 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).

https://glasscript.com/doctor/11110071/alexander-mut

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.